Domestic pharmaceutical companies are keeping eyes on gigantic hepatitis B drugs to catch the right moment

Domestic pharmaceutical companies in Korea have concentrated on launches of follow-up drugs for Baraclude(BMS) and Viread(Gilead), which divide the hepatitis B drug market into two parts.

Baraclude is in the state where domestic pharmaceutical companies already completed developing its generic drug and got approved by the government. Since the expiration date for substance patent is due on 9 N...